Kintara Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 17
- Market Cap
- -
- Website
- http://www.kintara.com
- Introduction
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
Phase 2
Recruiting
- Conditions
- Cutaneous Breast Cancer
- Interventions
- Combination Product: REM-001 photodynamic therapy
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Kintara Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05374915
- Locations
- 🇺🇸
Montefiore Einstein Center for Cancer Care, Bronx, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Expanded Access to VAL-083
- Conditions
- Cancer
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Kintara Therapeutics, Inc.
- Registration Number
- NCT03138629
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Phase 2
Active, not recruiting
- Conditions
- GliomaGlioblastoma MultiformeGBMBrain CancerGlioblastoma
- Interventions
- Drug: VAL-083 (Dianhydrogalactitol)
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Kintara Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03050736
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, China
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Phase 2
Active, not recruiting
- Conditions
- GBMBrain CancerGliomaGlioblastoma MultiformeGlioblastoma
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Kintara Therapeutics, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT02717962
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath